Assessment of benefit vs. risk of drug therapy: The potential for outcome analysis with flexible models

Paulo J G Lisboa, Ana S. Fernandes, José M. Fonseca, Chris Bajdik, Elia Biganzoli

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Pharmaceutical companies face twin pressures of improving the throughput of new products and responding to increased requirements by regulatory bodies for risk evaluation and mitigation both pre- and post-marketing. This paper gives a brief overview of flexible outcome models to improve the accuracy of these studies. The focus is on the discovery of niche populations in secondary analysis and monitoring of adverse events in observational studies of new products. Analytical results illustrate the power of the methods and they can be mapped onto Boolean filters to represent populations with particular benefit/risk ratios.

Original languageEnglish
Title of host publicationProceedings of the International Joint Conference on Neural Networks
DOIs
Publication statusPublished - 2010
Event2010 6th IEEE World Congress on Computational Intelligence, WCCI 2010 - 2010 International Joint Conference on Neural Networks, IJCNN 2010 - Barcelona, Spain
Duration: Jul 18 2010Jul 23 2010

Other

Other2010 6th IEEE World Congress on Computational Intelligence, WCCI 2010 - 2010 International Joint Conference on Neural Networks, IJCNN 2010
Country/TerritorySpain
CityBarcelona
Period7/18/107/23/10

ASJC Scopus subject areas

  • Software
  • Artificial Intelligence

Fingerprint

Dive into the research topics of 'Assessment of benefit vs. risk of drug therapy: The potential for outcome analysis with flexible models'. Together they form a unique fingerprint.

Cite this